- Home
- PFLT vs TNGX Comparison
PFLT vs TNGX Comparison
Compare PFLT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- TNGX
- Stock Information
- Founded
- PFLT 2010
- TNGX 2014
- Country
- PFLT United States
- TNGX United States
- Employees
- PFLT N/A
- TNGX N/A
- Industry
- PFLT Finance: Consumer Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- TNGX Health Care
- Exchange
- PFLT Nasdaq
- TNGX Nasdaq
- Market Cap
- PFLT 838.8M
- TNGX 735.0M
- IPO Year
- PFLT N/A
- TNGX N/A
- Fundamental
- Price
- PFLT $11.46
- TNGX $6.64
- Analyst Decision
- PFLT Strong Buy
- TNGX Strong Buy
- Analyst Count
- PFLT 2
- TNGX 8
- Target Price
- PFLT $12.00
- TNGX $15.14
- AVG Volume (30 Days)
- PFLT 635.8K
- TNGX 885.7K
- Earning Date
- PFLT 11-25-2024
- TNGX 11-06-2024
- Dividend Yield
- PFLT 10.71%
- TNGX N/A
- EPS Growth
- PFLT N/A
- TNGX N/A
- EPS
- PFLT 1.60
- TNGX N/A
- Revenue
- PFLT $166,565,000.00
- TNGX $42,509,000.00
- Revenue This Year
- PFLT $29.07
- TNGX $18.15
- Revenue Next Year
- PFLT $14.55
- TNGX N/A
- P/E Ratio
- PFLT $7.18
- TNGX N/A
- Revenue Growth
- PFLT 25.81
- TNGX 26.16
- 52 Week Low
- PFLT $9.69
- TNGX $6.33
- 52 Week High
- PFLT $12.63
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- PFLT 43.78
- TNGX 37.15
- Support Level
- PFLT $11.67
- TNGX $6.83
- Resistance Level
- PFLT $11.90
- TNGX $7.47
- Average True Range (ATR)
- PFLT 0.14
- TNGX 0.37
- MACD
- PFLT -0.01
- TNGX 0.11
- Stochastic Oscillator
- PFLT 6.32
- TNGX 27.31
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.